[Federal Register Volume 82, Number 177 (Thursday, September 14, 2017)]
[Proposed Rules]
[Pages 43197-43198]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-19491]



Food and Drug Administration

21 CFR Part 573

[Docket No. FDA-2017-F-4511]

Arcadia Biosciences, Inc.; Filing of Food Additive Petition 
(Animal Use)

AGENCY: Food and Drug Administration, HHS.

ACTION: Petition for rulemaking.


SUMMARY: The Food and Drug Administration (FDA or we) is announcing 
that Arcadia Biosciences, Inc. has filed a petition proposing that the 
food additive regulations be amended to provide for the safe use of 
gamma-linolenic acid (GLA) safflower oil as a source of omega-6 fatty 
acids in dry food for adult cats in the maintenance life stage.

DATES: The food additive petition was filed on May 1, 2017.

ADDRESSES: For access to the docket, go to https://www.regulations.gov 
and insert the docket number, found in brackets in the heading of this 
document, into the ``Search'' box and follow the prompts; and/or go to 
the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, 
MD 20852.

FOR FURTHER INFORMATION CONTACT: Carissa Doody, Center for Veterinary 
Medicine, Food and Drug Administration, 7519 Standish Pl., Rockville, 
MD 20855, 240-402-6283, [email protected].

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic 
Act (section 409(b)(5) (21 U.S.C. 348(b)(5)), notice is given that a 
food additive petition (FAP 2302) has been filed by Arcadia Biosciences 
Inc., 202 Cousteau Pl., Suite 200, Davis, CA 95618. The petition 
proposes to amend Title 21 of the Code of Federal Regulations (CFR) in 
part 573 (21 CFR part 573) Food Additives Permitted in Feed and

[[Page 43198]]

Drinking Water of Animals to provide for the safe use of GLA safflower 
oil as a source of omega-6 fatty acids in dry food for adult cats in 
the maintenance life stage.
    The petitioner has claimed that this action is categorically 
excluded under 21 CFR 25.32(r) because it is of a type that does not 
individually or cumulatively have a significant effect on the human 
environment. In addition, the petitioner has stated that to their 
knowledge, no extraordinary circumstances exist. If FDA determines a 
categorical exclusion applies, neither an environmental assessment nor 
an environmental impact statement is required. If FDA determines a 
categorical exclusion does not apply, we will request an environmental 
assessment and make it available for public inspection.

    Dated: September 8, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-19491 Filed 9-13-17; 8:45 am]